Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PRESS RELEASE AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutationsFirst-in-human...
-
Vallon’s board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON)...
-
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
-
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...
-
Combined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI...
-
PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
-
PHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
-
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) --...
-
- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with...
-
– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...